COVID-19. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: Therapeutic dose enoxaparin group: subcutaneous injections of enoxaparin, 1 mg/Kg, Twice a day, Tehran Chemie Co., if patients had a GFR lower than 30 mL/min inject
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: COVID-19 infection diagnosed by PCR Hospitalization requirement Having at least two signs of severe COVID-19 infection: (1) respiratory rate>30 (2) Spo250% in 48 hours
Exclusion criteria
Exclusion criteria: Pregnancy History of CVA in last month History of major surgery in last two weeks History of heparin induced thrombocytopenia Other definitive indications for therapeutic enoxaparin treatment Any contraindication for enoxaparin treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cumulative 6-month survival. Timepoint: 6 months after admission. Method of measurement: Visit or phonecall. | — |
Secondary
| Measure | Time frame |
|---|---|
| Hospitalization duration (days). Timepoint: After discharge or death. Method of measurement: Patient files.;Need for Intensive Care Unit admission. Timepoint: After discharge or death. Method of measurement: Patient files.;Need for mechanical ventilation. Timepoint: After discharge or death of patient. Method of measurement: Patient files.;Major bleeding defined by International Society on Thrombosis and Haemostasis criteria. Timepoint: After discharge or death. Method of measurement: Patient files. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammadreza Fattahi
Tehran University of Medical Sciences
Outcome results
None listed